Trial Profile
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-981 to Placebo in Subjects With Erosive Hand Osteoarthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2019
Price :
$35
*
At a glance
- Drugs Lutikizumab (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors AbbVie
- 14 Dec 2018 Results assessing efficcay and safety published in the Annals of the Rheumatic Diseases.
- 08 Nov 2017 Results assessing the efficacy and safety of ABT-981 in EHOA, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 17 Jun 2017 Primary endpoint (Change in pain as assessed by the Australian/Canadian Osteoarthritis Hand Index (AUSCAN NR3.1) pain subdomain score) has not been met, according to results presented at the 18th Annual Congress of the European League Against Rheumatism.